Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by longterm56on Jul 16, 2018 7:43am
211 Views
Post# 28319764

RE:RE:RE:RE:RE:RE:RE:RE:RE:Personally,

RE:RE:RE:RE:RE:RE:RE:RE:RE:Personally,
antiguru wrote: Just a short reply about investing an d capitalism. Is Russia and China capitalism, for they they too have stock markets for investors? The last I checked, investing and wealth creation are not capitalism's exclusive domain. You must have heard of Compassionate socialism too?You seem to think investors in socialist/social democracy markets must be heartless souls who are oblivious to those in great need. Just a reminder, there are HIV victims in non-capitalist markets too. I would hate to think investros there are all grumps.

Don't mean to spoil TH investors big expectation. Promise this is my last post. Have been a blast.


Thanks for the civics lesson, but I think you went a bit further than SPCEO1's intent.  It's always easy to rebut things that *you say* the other person said.

  -LT
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities